Poor Lilly.
They have quietly halted development of naveglitizar, a new class of diabetes medicine that also has been abandoned by two other drugmakers because of safety concerns.
Merrill Lynch analyst David Risinger called Lilly's move "the final nail in the coffin" for the drug class -- known as dual peroxisome proliferator-activated re ceptor alpha and gamma agonists -- which had been investigated as a treatment for Type 2 diabetes.
The announcement was buried in a Securities and Ex change Commission filing by its development partner, Ligand Pharmaceuticals. "Lilly informed (Ligand) that it had decided not to pursue further development at this time," the filing said.
AstraZeneca and BMS abandoned their dual-PPAR drugs, which in animal studies or late-stage clinical trials were associated with various side effects, including liver toxicity, cancer and heart problems.
Insider's view: Goodbye and good riddance! These drugs were a danger and BMS certainly did themselves no favours with the Pargluva "illusion of safety" Affair !
Source: George E. Jordan at the NJ Star-Ledger
They have quietly halted development of naveglitizar, a new class of diabetes medicine that also has been abandoned by two other drugmakers because of safety concerns.
Merrill Lynch analyst David Risinger called Lilly's move "the final nail in the coffin" for the drug class -- known as dual peroxisome proliferator-activated re ceptor alpha and gamma agonists -- which had been investigated as a treatment for Type 2 diabetes.
The announcement was buried in a Securities and Ex change Commission filing by its development partner, Ligand Pharmaceuticals. "Lilly informed (Ligand) that it had decided not to pursue further development at this time," the filing said.
AstraZeneca and BMS abandoned their dual-PPAR drugs, which in animal studies or late-stage clinical trials were associated with various side effects, including liver toxicity, cancer and heart problems.
Insider's view: Goodbye and good riddance! These drugs were a danger and BMS certainly did themselves no favours with the Pargluva "illusion of safety" Affair !
Source: George E. Jordan at the NJ Star-Ledger
2 comments:
Oh great - just celebrate loss of another potential drug.
Obviously you care more about bashing big pharma than in helping patients
Take a look at the Pargluva link. Then try and say that again!
Post a Comment